Appili Therapeutics Inc.

Halifax, NS

UEI
M6M7UQZCXG47
CAGE
L0BQ9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1344 Summer St #21, Halifax, NS B3H 0A8, Canada

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A novel negamycin analogue for the treatment of multi-drug resistant gram-negative bacterial infection W81XWH1910308 Defense Health Agency $894,367
Development of a negamycin analogue targeting the translational machinery in gram-negative drug-resistant pathogens for… W81XWH1710180 Medical Command (Army) $1,226,658

Quick answers

Is Appili Therapeutics Inc. registered in SAM.gov?

Yes. Appili Therapeutics Inc.'s SAM.gov registration is active through April 7, 2027.

What is Appili Therapeutics Inc.'s most recent federal award?

Appili Therapeutics Inc.'s most recent federal grant award is A novel negamycin analogue for the treatment of multi-drug resistant gram-negative bacterial infection (W81XWH1910308), from Defense Health Agency, on July 1, 2019.

On GovTribe

See Appili Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login